Adolescent nicotine sensitization and effects of nicotine on accumbal dopamine release in a rodent model of increased dopamine D2 receptor sensitivity

Behavioural Brain Research

Volumn 242, Issue 1, 2013, Pages 102-109

  Perna, Marla K ^a   Brown, Russell W ^a  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Adolescence; Dopamine D2 receptor; Locomotor sensitization; Microdialysis; Nicotine; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE 2 RECEPTOR; NICOTINE; QUINPIROLE; SODIUM CHLORIDE;

ADOLESCENCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DOPAMINE RELEASE; FEMALE; HABITUATION; LOCOMOTION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; REWARD; SCHIZOPHRENIA; SENSITIZATION; SEX DIFFERENCE; TOBACCO DEPENDENCE;

3,4-DIHYDROXYPHENYLACETIC ACID; AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONDITIONING, OPERANT; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMISTRY; FEMALE; HOMOVANILLIC ACID; MALE; MICRODIALYSIS; NICOTINE; NICOTINIC AGONISTS; NUCLEUS ACCUMBENS; PREGNANCY; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SELF ADMINISTRATION; TIME FACTORS;

EID: 84872300504     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.12.037     Document Type: Article

References (72)

1. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neuroscience and Therapeutics 2011, 17:118-132.
2. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 2006, 60:319-346.
3. Nord M., Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neuroscience and Therapeutics 2011, 17:97-103.
4. Kostrzewa R.M., Kostrzewa J.P., Nowak P., Kostrzewa R.A., Brus R. Dopamine D2 agonist priming in intact and dopamine-lesioned rats. Neurotoxicity Research 2004, 6:457-462.
5. Thacker S.K., Perna M.K., Ward J.J., Schaefer T.L., Williams M.T., Kostrzewa R.M., et al. The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. European Journal of Neuroscience 2006, 24:2075-2083.
6. Kostrzewa R.M. Dopamine receptor supersensitivity. Neuroscience and Biobehavioral Reviews 1995, 19:1-21.
7. Kostrzewa R.M., Brus R. Ontogenic homologous supersensitization of quinpirole-induced yawning in rats. Pharmacology Biochemistry and Behavior 1991, 39:517-519.
8. Cooper S.J., Rusk I.N., Barber D.J. Yawning induced by the selective dopamine D2 agonist N-0437 is blocked by the selective dopamine autoreceptor antagonist (+)-UH 232. Physiology and Behavior 1989, 45:1263-1266.
9. Collins G.T., Woods J.H. Narrowing in on compulsions: dopamine receptor functions. Experimental and Clinical Psychopharmacology 2008, 16:498-502.
10. Maple A.M., Perna M.K., Parlaman J.P., Stanwood G.D., Brown R.W. Ontogenetic quinpirole treatment produces long-lasting decreases in the expression of Rgs9, but increases Rgs17 in the striatum, nucleus accumbens and frontal cortex. European Journal of Neuroscience 2007, 26:2532-2538.
11. Celver J., Sharma M., Kovoor A. RGS9-2 mediates specific inhibition of agonist-induced internalization of D2-dopamine receptors. Journal of Neurochemistry 2010, 114:739-749.
12. Kovoor A., Seyffarth P., Ebert J., Barghshoon S., Chen C.K., Schwarz S., et al. D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. Journal of Neuroscience 2005, 25:2157-2165.
13. Rahman Z., Schwarz J., Gold S.J., Zachariou V., Wein M.N., Choi K.H., et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 2003, 38:941-952.
14. Seeman P., Ko F., Jack E., Greenstein R., Dean B. Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. Synapse 2007, 61:303-309.
15. Hymowitz N., Jaffe F.E., Gupta A., Feuerman M. Cigarette smoking among patients with mental retardation and mental illness. Psychiatric Services 1997, 48:100-102.
16. Van Dongen C.J. Smoking and persistent mental illness: an exploratory study. Journal of Psychosocial Nursing and Mental Health Services 1999, 37:26-34.
17. Weiser M., Reichenberg A., Grotto I., Yasvitzky R., Rabinowitz J., Lubin G., et al. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. American Journal of Psychiatry 2004, 161:1219-1223.
18. van Nimwegen L., de Haan L., van Beveren N., van den Brink W., Linszen D. Adolescence, schizophrenia and drug abuse: a window of vulnerability. Acta Psychiatrica Scandinavica 2005, 427(Suppl.):35-42.
19. Deas D., Brown E.S. Adolescent substance abuse and psychiatric comorbidities. Journal of Clinical Psychiatry 2006, 67:e02.
20. Baker A., Richmond R., Haile M., Lewin T.J., Carr V.J., Taylor R.L., et al. Characteristics of smokers with a psychotic disorder and implications for smoking interventions. Psychiatry Research 2007, 150:141-152.
21. French S.J., Humby T., Horner C.H., Sofroniew M.V., Rattray M. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Brain Research. Molecular Brain Research 1999, 67:124-136.
22. Kenny P.J., File S.E., Rattray M. Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Research. Molecular Brain Research 2000, 85:234-238.
23. Maggio R., Riva M., Vaglini F., Fornai F., Racagni G., Corsini G.U. Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. Journal of Neural Transmission 1997, 104:1113-1123.
24. Maggio R., Riva M., Vaglini F., Fornai F., Molteni R., Armogida M., et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. Journal of Neurochemistry 1998, 71:2439-2446.
25. Korsching S. The neurotrophic factor concept: a reexamination. Journal of Neuroscience 1993, 13:2739-2748.
26. Fanous S., Lacagnina M.J., Nikulina E.M., Hammer R.P. Sensitized activation of Fos and brain-derived neurotrophic factor in the medial prefrontal cortex and ventral tegmental area accompanies behavioral sensitization to amphetamine. Neuropharmacology 2011, 61:558-564.
27. Horger B.A., Iyasere C.A., Berhow M.T., Messer C.J., Nestler E.J., Taylor J.R. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. Journal of Neuroscience 1999, 19:4110-4122.
28. Filip M., Faron-Górecka A., Kuśmider M., Gołda A., Frankowska M., Dziedzicka-Wasylewska M. Alterations in BDNF and trkB mRNAs following acute or sensitizing cocaine treatments and withdrawal. Brain Research 2006, 1071:218-225.
29. Lu L., Dempsey J., Liu S.Y., Bossert J.M., Shaham Y. A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. Journal of Neuroscience 2004, 24:1604-1611.
30. Graham D.L., Edwards S., Bachtell R.K., DiLeone R.J., Rios M., Self D.W., et al. activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nature Neuroscience 2007, 10:1029-1037.
31. Pickens C.L., Airavaara M., Theberge F., Fanous S., Hope B.T., Shaham Y. Neurobiology of the incubation of drug craving. Trends in Neuroscience 2011, 34:411-420.
32. Sheppard B., Lehmann J., Cope Z.A., Brown R.W. Sex differences in nicotine sensitization and conditioned hyperactivity in adolescent rats neonatally treated with quinpirole: role of D2 and D3 receptor subtypes. Behavioral Neuroscience 2009, 123:1296-1308.
33. Perna M.K., Cope Z.A., Maple A.M., Longacre I.D., Correll J.A., Brown R.W. Nicotine sensitization in adult male and female rats quinpirole-primed as neonates. Psychopharmacology 2008, 199:67-75.
34. Lynch W.J., Roth M.E., Carroll M.E. Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology 2002, 164:121-137.
35. Zorrilla E.P. Multiparous species present problems (and possibilities) to developmentalists. Developmental Psychobiology 1997, 30:141-150.
36. Faraday M.M., Elliott B., Grunberg N.E. Nicotine's biobehavioral actions differ in adult vs. adolescent rats. Pharmacology Biochemistry and Behavior 2001, 70:675-689.
37. Smith R.F. Animal models of periadolescent substance abuse. Neurotoxicology and Teratology 2003, 25:291-301.
38. Faraday M.M., Elliott B.M., Phillips J.M., Grunberg N.E. Adolescent and adult male rats differ in sensitivity to nicotine's activity effects. Pharmacology Biochemistry and Behavior 2003, 74:917-931.
39. Hamilton K.R., Starosciak A.K., Chwa A., Grunberg N.E. Nicotine behavioral sensitization in Lewis and Fischer male rats. Experimental and Clinical Psychopharmacology 2012, 20:345-351.
40. Pierce R.C., Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Research Reviews 1997, 25:192-216.
41. Paxinos G., Watson C. The rat brain in Stereotaxic coordinates 1998, Elsevier, Massachusetts. 4th edition.
42. Cope Z.A., Huggins K.N., Sheppard A.B., Noel D.M., Roane D.S., Brown R.W. Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood. Synapse 2010, 64:289-300.
43. Nowak P., Brus R., Kostrzewa R.M. Amphetamine-induced enhancement of neostriatal in vivo microdialysate dopamine content in rats, quinpirole-primed as neonates. Polish Journal of Pharmacology 2001, 53:319-329.
44. Tizabi Y., Copeland R.L., Brus R., Kostrzewa R.M. Nicotine blocks quinpirole-induced behavior in rats: psychiatric implications. Psychopharmacology 1999, 145:433-441.
45. Kaiser S., Wonnacott S. Alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Molecular Pharmacology 2000, 58:312-318.
46. Fu Y., Matta S.G., Gao W., Sharp B.M. Local alpha-bungarotoxin-sensitive nicotinic receptors in the nucleus accumbens modulate nicotine-stimulated dopamine secretion in vivo. Neuroscience 2000, 101:369-375.
47. Meyer-Franke A., Wilkinson G.A., Kruttgen A., Hu M., Munro E., Hanson M.G., et al. Depolarization and cAMP elevation rapidly recruit TrkB to the plasma membrane of CNS neurons. Neuron 1998, 21:681-693.
48. Balkowiec A., Katz D.M. Activity-dependent release of endogenous brain-derived neurotrophic factor from primary sensory neurons detected by ELISA in situ. Journal of Neuroscience 2000, 20:7417-7423.
49. Russo S.J., Mazei-Robison M.S., Ables J.L., Nestler E.J. Neurotrophic factors and structural plasticity in addiction. Neuropharmacology 2008, 56:73-82.
50. Ghitza U.E., Zhai H., Wu P., Airavaara M., Shaham Y., Lu L. Role of BDNF and GDNF in drug reward and relapse: a review. Neuroscience and Biobehavioral Reviews 2010, 35:157-171.
51. Czubak A., Nowakowska E., Kus K., Burda K., Metelska J., Baer-Dubowska W., et al. Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacological Reports 2009, 61:1017-1023.
52. Aydin C., Oztan O., Isgor C. Nicotine-induced anxiety-like behavior in a rat model of the novelty-seeking phenotype is associated with long-lasting neuropeptidergic and neuroplastic adaptations in the amygdala: effects of the cannabinoid receptor 1 antagonist AM251. Neuropharmacology 2012, 63:1335-1345.
53. Kivinummi T., Kaste K., Rantamäki T., Castrén E., Ahtee L. Alterations in BDNF and phospho-CREB levels following chronic oral nicotine treatment and its withdrawal in dopaminergic brain areas of mice. Neuroscience Letters 2011, 491:108-112.
54. Grimm J.W., Lu L., Hayashi T., Hope B.T., Su T.P., Shaham Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. Journal of Neuroscience 2003, 23:742-747.
55. Lu L., Grimm J.W., Dempsey J., Shaham Y. Cocaine seeking over extended withdrawal periods in rats: different time courses of responding induced by cocaine cues versus cocaine priming over the first 6 months. Psychopharmacology 2004, 176:101-108.
56. Reid M.S., Ho L.B., Berger S.P. Behavioral and neurochemical components of nicotine sensitization following 15-day pretreatment: studies on contextual conditioning. Behavioural Pharmacology 1998, 9:137-148.
57. Segal D.S., Browne R.G., Bloom F., Ling N., Guillemin R. Beta-Endorphin: endogenous opiate or neuroleptic?. Science 1977, 198:411-414.
58. Gaytan O., Swann A.C., Dafny N. Effects of amphetamine at the beginning of the light cycle on multiple indices of motor activity in the rat. European Journal of Pharmacology 1996, 300:1-8.
59. Belluzzi J.D., Lee A.G., Oliff H.S., Leslie F.M. Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats. Psychopharmacology 2004, 174:389-395.
60. Schochet T.L., Kelley A.E., Landry C.F. Differential behavioral effects of nicotine exposure in adolescent and adult rats. Psychopharmacology 2004, 175:265-273.
61. Andersen S.L., Teicher M.H. Sex differences in dopamine receptors and their relevance to ADHD. Neuroscience and Biobehavioral Reviews 2000, 24:137-141.
62. Brown R.W., Maple A.M., Perna M.K., Sheppard A.B., Cope Z.A., Kostrzewa R.M. Schizophrenia and substance abuse comorbidity: nicotine addiction and the neonatal quinpirole model. Developmental Neuroscience 2012, 34:140-151.
63. LeDuc P.A., Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology 1995, 121:407-427.
64. Leonard S., Adler L.E., Benhammou K., Berger R., Breese C.R., Drebing C., et al. Smoking and mental illness. Pharmacology Biochemistry and Behavior 2001, 70:561-570.
65. Martin L.F., Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. International Review of Neurobiology 2007, 78:225-246.
66. Martin L.F., Kem W.R., Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 2004, 174:54-64.
67. Ahnallen C.G., Liverant G.I., Gregor K.L., Kamholz B.W., Levitt J.J., Gulliver S.B., et al. The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. Psychiatry Research 2012, 196:9-14.
68. Glassman A.H. Cigarette smoking: implications for psychiatric illness. American Journal of Psychiatry 1993, 150:546-553.
69. Winterer G. Why do patients with schizophrenia smoke?. Current Opinion in Psychiatry 2010, 23:112-119.
70. McClernon F.J. Neuroimaging of nicotine dependence: key findings and application to the study of smoking-mental illness comorbidity. Journal of Dual Diagnosis 2009, 5:168-178.
71. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biological Psychiatry 1999, 46:56-72.
72. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. American Journal of Psychiatry 1998, 155:761-767.